AstraZeneca Rebounds, But Trend Still Looks Weak

For investors, the key issue is whether support from DZ Bank marks the start of a more durable rerating or just a relief bounce after a sharp pullback. AstraZeneca’s shares were trading above 208 in late February before sliding back, and the stock’s RSI reading of 32.6 suggests it is no longer deeply oversold, but it is still fragile.

The recent recovery comes against a broader backdrop of selective strength in defensive and healthcare names, as investors rotate toward companies with dependable cash flow and pricing power. That theme has gained traction as analysts across other sectors have rewarded companies that can lift guidance, while punishing firms where growth looks less sustainable.

AstraZeneca’s next catalyst will be whether sentiment can translate into a cleaner break back above the 50-day average. Until then, the stock is likely to trade as a battleground between buyers betting on earnings resilience and sellers using the recent rebound to reduce exposure.